X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
SST-6007 (Sildenafil Citrate) is a topical PDE-5 inhibitor. It is being evaluated in phase 2 clinical trials in women with female sexual arousal disorder.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: SST-6007
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Strategic Science & Technologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2024
Details:
The net proceeds will support the development of Dare’s late-stage candidates, including SST-6007, a first-in-class topical sildenafil product candidate in development as an over-the-counter treatment for Female Sexual Arousal Disorder.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: SST-6007
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Financing December 26, 2023
Details:
ASP-001 (sildenafil citrate oral spray) is a PDE-5 inhibitor, administered via a spray pump, which is being investigated for the treatment of erectile dysfunction.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: ASP-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
SST-6007 (sildenafil citrate), a proprietary cream formulation that is specifically designed to locally increase blood flow to the vulvar-vaginal tissue in women, for Female Sexual Arousal Disorder (FSAD).
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: SST-6007
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2023
Details:
Sildenafil oral suspension is an oral liquid suspension of sildenafil citrate administered via a metered-dose pump that dispenses 12.5 mg of sildenafil per actuation act as phosphodiesterase-5 inhibitor, which being investigated for the treatment of erectile dysfunction.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: ASP-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
ASP-001 (sildenafil citrate oral spray) is a PDE-5 inhibitor, administered via a spray pump, which is being investigated for the treatment of erectile dysfunction.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: ASP-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Details:
Daré intends to use the proceeds for the development of SST-6007 (sildenafil citrate), a proprietary cream formulation that is specifically designed to locally increase blood flow to the vulvar-vaginal tissue in women, for Female Sexual Arousal Disorder (FSAD).
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: SST-6007
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 30, 2023
Details:
Mango (sildenafil citrate) mango-flavored, rapid dissolve tablet is a Phosphodiesterase-5 inhibitor, which is being indicated for the treatment of erectile dysfunction.
Lead Product(s): Sildenafil Citrate,Oxytocin,L-Arginine
Therapeutic Area: Psychiatry/Psychology Product Name: Mango
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023
Details:
ASP-001 (sildenafil citrate oral spray) is a PDE-5 inhibitor, administered via a spray pump, which is being investigated for the treatment of erectile dysfunction.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: ASP-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
SST-6007 (sildenafil citrate) cream is applied locally to the vaginal tissue prior to sexual activity to facilitate vasodilation and increase blood flow directly to the genital tissue to improve the physical arousal responsein womens with FSAD.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: SST-6007
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Strategic Science & Technologies, LLC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
Liqrev (sildenafil) is the PDE5 inhibitor and First and Only Ready-made FDA-approved Liquid Suspension is indicated for the treatment of pulmonary arterial hypertension.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Liqrev
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
Lybrido is a novel combination tablet, consisting of a testosterone coating for sublingual administration and an inner-core component containing the PDE-5 inhibitor, sildenafil that used for the treatment of Female Sexual Interest/Arousal Disorder (FSIAD).
Lead Product(s): Sildenafil Citrate,Testosterone
Therapeutic Area: Psychiatry/Psychology Product Name: Lybrido
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2023
Details:
SST-6007 (sildenafil citrate) Cream, 3.6% is a PDE-5 inhibitor, which being investigated for the treatment of Women with Female Sexual Arousal Disorder.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: SST-6007
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Strategic Science & Technologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
Lybrido is a novel combination tablet, consisting of a testosterone coating for sublingual administration and an inner-core component containing the PDE-5 inhibitor, sildenafil. It increases central sexual motivation and physiological sexual responses.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: Lybrido
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
Sildenafil citrate cream is applied locally to the vaginal tissue prior to sexual activity to facilitate vasodilation and increase blood flow directly to the genital tissue to improve the physical arousal responsein womens with FSAD.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
Lybrido (sildenafil) intends to increase central sexual motivation and physiological sexual responses. It consists of a novel combination tablet containing a testosterone coating for sublingual administration and an inner-core component made of the PDE-5 inhibitor, sildenafil.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: Lybrido
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
Hezkue (sildenafil), inhibits cGMP-specific PDE-5. Penile erection involves corpus cavernosum relaxation, mediated by NO and cGMP. The biological actions of cGMP are terminated by phosphodiesterase enzymes and PDE-5 is the major cGMP metabolising enzyme in this tissue.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: Hezkue
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
Sildenafil is a selective inhibitor of cyclic GMP specific phosphodiesterase (PDE) type 5, the predominant enzyme metabolizing cyclic GMP in the corpus cavernosum. It is indicated for treating pulmonary arterial hypertension in adults.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Revatio-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
Sildenafil Cream is a proprietary topical formulation of sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor, being developed as a first-in-category option for the treatment of FSAD.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
The license grants Taiba the exclusive right and license to market, promote, and distribute Viagra as Sildenafil Spray in the territory described in the license, which covers Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, Oman, Lebanon, Egypt, and Iraq.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: Viagra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Taiba Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 04, 2022
Details:
Sildenafil Cream is a proprietary topical formulation of sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor, being developed as a first-in-category option for the treatment of FSAD.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
Lybrido (sildenafil) is a unique therapeutic concept, both by its combination of testosterone and sildenafil, as well as by its dual route, dual release, fixed dose system, and as such achieving the optimal synergy of both active ingredients.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: Lybrido
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2022
Details:
Lybrido (sildenafil) increases central sexual motivation and physiological sexual responses, such as swelling of vaginal erectile tissue and lubrication.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: Lybrido
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
Sildenafil oral spray is an oral liquid suspension of sildenafil citrate administered via a spray pump that dispenses 12.5 mg of sildenafil per push. The discreet and easy-to-carry oral spray allows the user to customize dosing and avoid pill splitting tablet medication.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aspargo Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 21, 2022
Details:
BANDOL®, offered in a convenient and discreet metered dose container that delivers the equivalent of 12.5 mg of Sildenafil per actuation, is manufactured in Spain and is prescribed predominantly by primary care physicians and urologists.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: Bandol
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aspargo Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 04, 2022
Details:
The new funding will be used to carry out a pivotal phase 3 trial with its therapy Lybrido in 516 patients across Europe. Lybrido showed clinical relevance and statistical significance in a phase 2b clinical trial, clearly meeting the primary endpoints.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: Lybrido
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $8.5 million Upfront Cash: Undisclosed
Deal Type: Financing March 29, 2022
Details:
Collaboration will sell in Mexico a number of CURE’s OTC and medical compounds (sildenafil citrate) that utilize CUREform™, CURE’s patented drug delivery platform for oral thin film (OTF). Cure is in discussions with several large distributors in Mexico and Latin America.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: CUREfilm Blue
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Milagro Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 03, 2022
Details:
Freya Pharma has been established to further advance two compounds for the FSIAD-disorder, Lybrydo and Lybrydos, that have shown clinical and statistical relevance in an earlier phase 2b clinical trial, clearly meeting the primary endpoints.
Lead Product(s): Sildenafil Citrate,Testosterone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Lybrido
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Emotional Brain BV
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 17, 2021
Details:
CUREfilm Blue™ utilizes the Company’s patented and proprietary fast-dissolving drug delivery platform, known as CUREfilm™, to deliver the active pharmaceutical ingredient (API) sildenafil citrate.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: CUREfilm Blue
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2021
Details:
Funds will support the branding & product launch of Cure’s consumer products by newly acquired Sera Labs and the advancement of CURE’s clinical pharmaceutical pipeline
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Endocrinology Product Name: CUREfilm Blue
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Axiom Capital Management
Deal Size: $10.0 million Upfront Cash: $4.0 million
Deal Type: Financing November 02, 2020
Details:
Aspargo’s Sildenafil Oral Spray is an oral liquid suspension of sildenafil citrate administered via a spray pump that dispenses 12.5 mg of sildenafil citrate per push of the pump (referred to as ASP-001) or via an individual single liquid unit dispensing 100 mg per unit.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Endocrinology Product Name: Viagra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Farmalider SA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 29, 2020
Details:
FDA supported Aspargo’s plan to conduct a single dose bioequivalent study to assess the pharmacokinetics, bioequivalency, tolerability and safety of the Company’s Sildenafil Oral Spray drug candidate.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
Details:
Agreement provides Roman members with erectile dysfunction treatment backed by Pfizer’s quality manufacturing standards and supply chain excellence.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Greenstone LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
